Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 9/20 | 0.40 |
| ▸ | HTR1A | P08908 | 2/20 | 0.38 |
| ▸ | DRD2 | P14416 | 2/20 | 0.38 |
| ▸ | HTR2A | P28223 | 2/20 | 0.38 |
| ▸ | UGCG | Q16739 | 1/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.32 |
| ▸ | DHPS | P49366 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20820768 | 0.83 | IDH1 (0.38) | IDH1UGCGLRRK2DHPS | |
| SCHEMBL20820769 | 0.80 | IDH1 (0.36) | IDH1UGCGLRRK2DHPS | |
| SCHEMBL17050409 | 0.80 | IDH1 (0.41) | IDH1UGCGLRRK2DHPS | |
| SCHEMBL12164213 | 0.75 | MEN1 (0.45) | IDH1HTR2ADHPSMEN1MAPT | |
| SCHEMBL25961893 | 0.70 | IDH1 (0.43) | IDH1 | |
| SCHEMBL23350137 | 0.67 | MAPK1 (0.48) | IDH1LRRK2DHPSMEN1MAPT | |
| SCHEMBL29620459 | 0.67 | IDH1 (0.40) | IDH1DHPS | |
| SCHEMBL18793867 | 0.65 | IDH1 (0.38) | IDH1LRRK2 | |
| SCHEMBL23228381 | 0.65 | IDH1 (0.57) | IDH1UGCGLRRK2MEN1MAPT | |
| SCHEMBL19778863 | 0.65 | IDH1 (0.53) | IDH1LRRK2DHPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3279187-B1 | 9-MEMBERED FUSED RING DERIVATIVE | SHIONOGI & CO (JP) | 2021-06-02 | — | — | EP | disclosed |
| US-20180079727-A1 | 9-MEMBERED FUSED RING DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2018-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180079727-A1 | 9-MEMBERED FUSED RING DERIVATIVE | ACSS2, AGTR2, ACSL3 | IDH1 129/4885HTR1A 4290/4885DRD2 2763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.